2SEIFER M,PATTY A,FARAJ A,et al.In vitro studies on the mechanism of action of L-nucleoside inhibitors of hepatitis B virus replication reveal differences between LdT and lamivudine[J].Hepatology,2001,34(S1):635A.
3KIM JW,PARK SH,LOUIE SG.Telbivudine:a novel nucleoside analog for chronic hepatitis B[J].Ann Pharmacother,2006,40 (3):472-478.
5ZHOU XJ,LIM SG,LLOYD DM,et al.Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection:pharmacodynamic implications[J].Antimicrob Agents Chemother,2006,50(3):874 -879.
6LAI CL,LIM SG,BROWN NA,et al.A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection[J].Hepatology,2004,40 (3):719 -726.
7LAI CL,LEUNG NWY,TEO EK,et al.Results of a one-year international phase Ⅱb comparative trial of telbivudine,lamivudine,and the combination,in patients with chronic hepatitis B[J].Hepatology,2003,38 (4 Suppl1):262A.
8LAI CL,LEUNG N,TEO EK,et al.A 1-year trial of telbivudine,lamivudine,and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B[J].Gastroenterology,2005,129(2):528 -536.
9LAI CL,GANE E,LIAW YF,et al.Telbivudine(LdT) vs lamivudine for chronic hepatitis B:First-year results from the International Phase Ⅲ GLOBE Trial[J].Hepatology,2005,42 (4 Suppl 1):748A.
10ZHOU XJ,MYERS M,CHAO G,et al.Clinical pharmacokinetics of telbivudine,a potent antiviral for hepatitis B,in subjects with impaired hepatic or renal function[R].39th EASL,2004.
